证券代码：688683 证券简称：莱尔科技 公告编号：2026-011 广东莱尔新材料科技股份有限公司 关于签订募集资金专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会于2025年12月16日核发的《关于同意广东莱尔新材料科技股份有限公司向 特定对象发行股票注册的批复》（证监许可〔2025〕2795号），广东莱尔新材料科技股份有限公司（以 下简称"公司"或"莱尔科技"）获准向特定对象发行人民币普通股5,919,871股，每股面值1.00元，每股发 行价格为人民币26.96元，募集资金总额为人民币159,599,722.16元，扣除发行费用人民币5,782,727.87元 后，公司本次募集资金净额为人民币153,816,994.29元。 上述募集资金总额为人民币159,599,722.16元，主承销商世纪证券有限责任公司（以下简称"世纪证 券"）扣除承销费用人民币1,886,792.45元（不含税）后，剩余募集资金人民币157,712,929.71元，已于 2025年12 ...

证券代码：603376 证券简称：大明电子 公告编号：2026-001 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意大明电子股份有限公司首次公开发行股票注册的批复》（证监许 可〔2025〕1643号）同意注册，并经上海证券交易所同意，大明电子股份有限公司（以下简称"公司"） 向社会公开发行人民币普通股（A股）4,000.10万股，发行价格为12.55元/股，本次发行募集资金总额为 502,012,550.00元，扣除发行费用78,190,571.41元（不含增值税）后，募集资金净额为423,821,978.59 元。容诚会计师事务所（特殊普通合伙）对公司本次公开发行新股的资金到位情况进行了审验并出具了 《验资报告》（容诚验字[2025]230Z0132号）。 二、募集资金管理情况 为了规范公司募集资金的存放、使用和管理，维护投资者的合法权益，确保公司募投项目顺利开展，提 高募集资金使用效率，根据《上市公司募集资金监管规则》《上海证券交易所上市公司自律监管指引第 1号 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 2020年6月30日，本公司与子公司南京安赛莱医药科技有限公司、广发银行股份有限公司扬州分行、中 国建设银行股份有限公司南京鼓楼支行和华泰联合证券签署《募集资金专户存储五方监管协议》,在广 发银行股份有限公司扬州分行开设募集资金专项账户(账号：9550880058239300203),在中国建设银行股 份有限公司南京鼓楼支行(建宁路支行)开设募集资金专项账户(账号：32050159524609999996)。 2020年6月30日，本公司与子公司扬州艾迪医药科技有限公司、江苏银行股份有限公司扬州分行和华泰 联合证券签署《募集资金专户存储四方监管协议》,在江苏银行股份有限公司扬州分行(唐城支行)开设募 集资金专项账户(账号：90160188000125327)。 2022年1月19日，公司召开第一届董事会第二十一次会议和第一届监事会第十七次会议，审议通过了 《关于变更部分募集资金专项账户及新增募集资金专项账户的议案》。 2022年1月26日，本公司与中国建设银行股份有限公司江苏省分行和华泰联合证券签署《募集资金专户 存储三方监管协议》,在中国建设银行股份有限公司 ...

证券代码：603887 证券简称：城地香江 公告编号：2026-003 上海城地香江数据科技股份有限公司 ● 截至2026年1月13日，公司已累计归还临时补充流动资金的闲置募集资金人民币19,000万元。 一、募集资金临时补充流动资金情况 关于归还临时补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至2026年1月13日，公司已将用于补充流动资金的19,000万元闲置募集资金按时归还至公司募集资金 专用账户，并及时将上述资金归还情况通知了保荐机构和保荐代表人。 ■ 上海城地香江数据科技股份有限公司（以下简称"公司"）于2025年1月15日召开第五届董事会第十三次 会议和第五届监事会第九次会议，分别全票审议通过了《关于使用部分闲置募集资金临时补充流动资金 的议案》，同意公司使用部分闲置募集资金19,000万元临时补充公司流动资金，使用期限为自董事会审 议通过之日起不超过12个月，详见2025年1月16日公司在上海证券交易所网站(http://www.sse.com.cn/)披 露的 ...

（编辑 楚丽君） 证券日报网讯 1月13日，甘咨询在互动平台回答投资者提问时表示，公司严格按照《上市公司募集资金 监管规则》和《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等有关规定 使用暂时闲置募集资金开展现金管理，并及时履行信息披露义务。公司董事会持续关注募集资金存放、 管理和使用情况，有效防范投资风险，提高募集资金使用效益，无其他应披露而未披露的信息。 ...

中国经济网北京1月13日讯 广康生化(300804.SZ)1月9日发布关于公司及相关人员收到广东证监局警 示函的公告。 2023年6月27日，广康生化在深交所创业板上市，发行数量为1,850.00万股，占发行后总股本的 25.00%，本次发行全部为新股，发行价格为42.45元/股。目前该股处于破发状态。 广康生化发行募集资金总额为78,532.50万元，扣除不含税发行费用后，实际募集资金净额为 69,736.57万元。广康生化实际募资净额比原拟募资多617.79万元。公司2023年6月19日披露的招股说明 书显示，广康生化拟募集资金69,118.78万元，用于年产4500吨特殊化学品建设项目、补充流动资金。 广康生化发行的保荐机构为华泰联合证券有限责任公司，保荐代表人为张新星、刘恺。公司本次发 行费用总额为8,795.93万元，其中华泰联合证券有限责任公司获得承销及保荐费用6,582.60万元。 (责任编辑：华青剑) 2023年7月至2025年8月期间，公司经相关审议程序通过使用募集资金进行现金管理的议案后，循环 使用募集资金滚动购买179笔理财产品，经查，其中有158笔为非保本理财产品，2023年、2024 ...

Core Viewpoint - The company, Anhui Xinke New Materials Co., Ltd., is planning to issue A-shares to specific investors, aiming to raise funds for repaying bank loans and supplementing working capital, which is expected to enhance its capital structure and reduce financial costs [11][15]. Group 1: Fundraising and Financial Impact - The total amount of funds to be raised is estimated at 350 million yuan, with the issuance of approximately 109,034,267 shares [12]. - The company anticipates that the issuance will dilute immediate returns, with potential impacts on key financial metrics, including earnings per share [14]. - The company has outlined specific measures to mitigate the dilution of immediate returns, including improving operational efficiency and enhancing management practices [16][17]. Group 2: Governance and Compliance - The company has established a fundraising management system to ensure compliance with relevant laws and regulations, and to manage the raised funds effectively [4][17]. - The board of directors has been authorized to make necessary adjustments to the fundraising plan in response to changes in regulations or market conditions [3][4]. - Commitments from major shareholders and management have been made to ensure the fulfillment of measures aimed at compensating for the dilution of immediate returns [20][21]. Group 3: Shareholder Engagement and Future Strategy - The company has committed to maintaining a robust dividend policy to protect shareholder interests, particularly for minority shareholders [19]. - The board has proposed a plan for the first extraordinary general meeting of 2026 to discuss these matters further [9][10]. - The company aims to strengthen its competitive position in the market through strategic investments and operational improvements following the fundraising [15][16].

Core Viewpoint - The company has utilized its own funds to pay for part of the fundraising investment projects and will replace these amounts with raised funds, amounting to RMB 29.2643 million, in compliance with regulations regarding fund replacement within six months of payment [2][8]. Fundraising Basic Situation - The company raised a total of RMB 1,827.1 million through a non-public offering of 396,334,048 shares at a price of RMB 4.61 per share, with a net amount of RMB 1,814.1 million after deducting issuance costs [3][4]. - The funds were deposited on January 16, 2023, and are managed in a dedicated account with a tripartite supervision agreement in place [3][4]. Investment Project Situation - The company has adjusted its fundraising investment projects, extending the timeline for several projects to December 31, 2027, without changing the total investment amount or project content [4]. Use of Own Funds and Replacement - The necessity for using own funds arises from difficulties in direct payments from the fundraising account, particularly for employee salaries and social insurance, which must be processed through the company's basic deposit account [6]. - The process for replacing own funds with raised funds includes submitting payment requests, maintaining detailed records, and ensuring compliance with approval procedures [7]. Impact on the Company - The use of own funds for project payments and subsequent replacement with raised funds is expected to enhance the efficiency of fund utilization and overall operational management, benefiting the company and its shareholders [9]. Special Opinions - The sponsor institution has confirmed that the company's actions regarding the use of own funds and their replacement with raised funds have been properly approved and do not affect the normal implementation of fundraising projects [10].

Core Viewpoint - ST Pava has decided to terminate the investment project for an annual production of 15,000 tons of ternary precursor materials, citing changes in the industry and market environment as the primary reason for this decision [1][4] Group 1: Project Termination Details - The company announced the termination of the "annual production of 15,000 tons ternary precursor project" on January 9, 2026, which requires shareholder approval [1] - The project was initially part of a public offering that raised approximately 17.43 billion yuan, with a net amount of about 15.95 billion yuan after expenses [1] - The remaining funds from the terminated project will continue to be managed in a dedicated account [1] Group 2: Revised Investment Projects - The revised investment plan includes three projects: an annual production of 25,000 tons ternary precursor project (investment of 787.11 million yuan, with 701.88 million yuan used by November 30, 2025), the terminated 15,000 tons project (investment of 472.27 million yuan, with 190.94 million yuan used), and working capital supplementation (investment of 250 million yuan, with 253.13 million yuan used) [2] - The total investment for these projects is approximately 1.51 billion yuan, with 1.14 billion yuan already utilized [2] Group 3: Project Status and Financials - The annual production of 25,000 tons ternary precursor project has been completed and is operational, while the 15,000 tons project was initially planned for a 24-month construction period, now extended to August 2026 [3] - As of November 30, 2025, the terminated project has utilized 190.94 million yuan, leaving approximately 301.29 million yuan in remaining funds [3] Group 4: Rationale for Termination - The decision to terminate the project is based on significant changes in the industry and market conditions, necessitating a dynamic adjustment of business strategies and capacity planning [4] - The company faces challenges with raw material costs and market competition, which could lead to inefficiencies in fund usage if the project were to continue [4] - The termination is expected to enhance the efficiency of fund usage and optimize resource allocation, aligning with the company's future strategic goals [4]

Core Viewpoint - The company has decided to terminate the investment project for the annual production of 15,000 tons of ternary precursor due to changes in market conditions and industry dynamics, which will optimize resource allocation and improve the efficiency of fund usage [7][8][10]. Fundraising Overview - The company raised a total of RMB 1,742,885,617.16 through its initial public offering, with a net amount of RMB 1,595,130,043.93 after deducting issuance costs [1]. - All raised funds are managed in a dedicated account, with agreements in place with commercial banks and the sponsor [2]. Investment Project Status - The terminated project had an intended investment of RMB 47,226.97 million and was initially planned for a 24-month construction period [7]. - As of November 30, 2025, the project had utilized RMB 19,093.98 million, leaving a remaining balance of RMB 30,128.7307 million in the dedicated account [7]. Reasons for Termination - The decision to terminate the project was influenced by significant changes in the industry and market environment, which necessitated a dynamic adjustment of the company's business strategy and capacity planning [8]. - The company faces challenges due to reliance on imported raw materials, leading to fluctuations in product pricing and competitive disadvantages [8]. - The overall market competition has intensified, and the current production capacity is deemed sufficient to meet existing business demands, making further investment in the project unnecessary [9]. Impact on the Company - The termination of the project is expected to have no significant adverse effects on the company's normal operations and is aligned with its strategic development goals [10]. - The company will ensure compliance with relevant regulations regarding the management and usage of raised funds [10]. Board Meeting and Approval Process - The board of directors approved the termination of the project during a meeting held on January 9, 2026, and the decision will be submitted for shareholder approval [11][16].